|
1
|
Zhao W, Mori H, Tomiga Y, Tanaka K, Perveen R, Mine K, Inadomi C, Yoshioka W, Kubotsu Y, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Zhao Y, Ozaki I, Nagafuchi S, Kawaguchi A, Aishima S, Anzai K, Takahashi H. HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. Genes (Basel) 2022; 13:genes13071265. [PMID: 35886046 PMCID: PMC9323248 DOI: 10.3390/genes13071265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 07/01/2022] [Accepted: 07/14/2022] [Indexed: 11/29/2022] Open
Abstract
There is an association between nonalcoholic fatty liver disease (NAFLD) and atherosclerosis, but the genetic risk of atherosclerosis in NAFLD remains unclear. Here, a single-nucleotide polymorphism (SNP) of the heat shock 70 kDa protein 8 (HSPA8) gene was analyzed in 123 NAFLD patients who had been diagnosed using a liver biopsy, and the NAFLD phenotype including the maximum intima–media thickness (Max-IMT) of the carotid artery was investigated. Patients with the minor allele (A/G or G/G) of rs2236659 showed a lower serum heat shock cognate 71 kDa protein concentration than those with the major A/A allele. Compared with the patients with the major allele, those with the minor allele showed a higher prevalence of hypertension and higher Max-IMT in men. No significant associations between the HSPA8 genotype and hepatic pathological findings were identified. In decision-tree analysis, age, sex, liver fibrosis, and HSPA8 genotype were individually associated with severe carotid artery atherosclerosis (Max-IMT ≥ 1.5 mm). Noncirrhotic men aged ≥ 65 years were most significantly affected by the minor allele of HSPA8. To predict the risk of atherosclerosis and cardiovascular disease, HSPA8 SNP genotyping might be useful, particularly for older male NAFLD patients.
Collapse
Affiliation(s)
- Wenli Zhao
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
- Liver Center, Saga University Hospital Faculty of Medicine, Saga University, Saga 849-8501, Japan; (H.I.); (S.O.)
| | - Hitoe Mori
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Yuki Tomiga
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Kenichi Tanaka
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Rasheda Perveen
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Keiichiro Mine
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
- Division of Mucosal Immunology, Research Center for Systems Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan
| | - Chika Inadomi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Wataru Yoshioka
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Yoshihito Kubotsu
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Hiroshi Isoda
- Liver Center, Saga University Hospital Faculty of Medicine, Saga University, Saga 849-8501, Japan; (H.I.); (S.O.)
| | - Takuya Kuwashiro
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Satoshi Oeda
- Liver Center, Saga University Hospital Faculty of Medicine, Saga University, Saga 849-8501, Japan; (H.I.); (S.O.)
| | - Takumi Akiyama
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Ye Zhao
- Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250014, China;
| | - Iwata Ozaki
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
- Health Administration Centre, Saga Medical School, Saga University, Saga 849-8501, Japan
| | - Seiho Nagafuchi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Atsushi Kawaguchi
- Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan;
| | - Shinichi Aishima
- Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga 849-8501, Japan;
| | - Keizo Anzai
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
| | - Hirokazu Takahashi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (W.Z.); (H.M.); (Y.T.); (K.T.); (R.P.); (K.M.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (I.O.); (S.N.); (K.A.)
- Liver Center, Saga University Hospital Faculty of Medicine, Saga University, Saga 849-8501, Japan; (H.I.); (S.O.)
- Correspondence:
| |
Collapse
|
|
2
|
Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021; 11:diagnostics11010132. [PMID: 33467114 PMCID: PMC7830542 DOI: 10.3390/diagnostics11010132] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 01/11/2021] [Accepted: 01/13/2021] [Indexed: 12/17/2022] Open
Abstract
Access to imaging is limited for diagnosing nonalcoholic fatty liver disease (NAFLD) in general populations. This study evaluated the diagnostic performance of noninvasive and nonimaging indexes to predict NAFLD in the general Japanese population. Health checkup examinees without hepatitis virus infection or habitual alcohol drinking were included. Fatty liver was diagnosed by ultrasonography. The hepatic steatosis index (HSI), Zhejiang University (ZJU) index, and fatty liver index (FLI) were determined, and risk of advanced liver fibrosis was evaluated by the fibrosis-4 index. NAFLD was diagnosed in 1935 (28.0%) of the 6927 subjects. The area under the receiver operating characteristic (AUROC) curve of the HSI, ZJU index, and FLI was 0.874, 0.886, and 0.884, respectively. The AUROC of the ZJU index (p < 0.001) and FLI (p = 0.002) was significantly greater than that for the HSI. In subjects with a high risk of advanced fibrosis, the sensitivity of the HSI, ZJU index, and FLI were 88.8%, 94.4%, and 83.3% with a low cut-off value and the specificity was 98.5%, 100%, and 100% with a high cut-off value. In conclusion, all indexes were useful to diagnose NAFLD in the general Japanese population and in subjects with potentially advanced liver fibrosis.
Collapse
Affiliation(s)
- Kenichiro Murayama
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
- Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga 840-8571, Japan;
| | - Michiaki Okada
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Kenichi Tanaka
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Chika Inadomi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Wataru Yoshioka
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Yoshihito Kubotsu
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Tomomi Yada
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (T.Y.); (H.I.); (S.O.); (Y.E.)
| | - Hiroshi Isoda
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (T.Y.); (H.I.); (S.O.); (Y.E.)
| | - Takuya Kuwashiro
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Satoshi Oeda
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (T.Y.); (H.I.); (S.O.); (Y.E.)
| | - Takumi Akiyama
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Noriko Oza
- Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga 840-8571, Japan;
| | - Hideyuki Hyogo
- Department of Gastroenterology and Hepatology, JA Hiroshima General Hospital, Hatsukaichi 738-8503, Japan;
| | - Masafumi Ono
- Tokyo Women’s Medical University Medical Center East, Internal Medicine, Tokyo 116-8567, Japan;
| | - Takumi Kawaguchi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (T.K.); (T.T.)
| | - Takuji Torimura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan; (T.K.); (T.T.)
| | - Keizo Anzai
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
| | - Yuichiro Eguchi
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (T.Y.); (H.I.); (S.O.); (Y.E.)
- Department of Clinical Gastroenterology, Eguchi Hospital, Ogi 845-0032, Japan
| | - Hirokazu Takahashi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (K.M.); (M.O.); (K.T.); (C.I.); (W.Y.); (Y.K.); (T.K.); (T.A.); (K.A.)
- Liver Center, Saga University Hospital, Faculty of Medicine, Saga University, Saga 849-8501, Japan; (T.Y.); (H.I.); (S.O.); (Y.E.)
- Correspondence: ; Tel.: +81-952-34-3010
| |
Collapse
|
|
3
|
Inadomi C, Takahashi H, Ogawa Y, Oeda S, Imajo K, Kubotsu Y, Tanaka K, Kessoku T, Okada M, Isoda H, Akiyama T, Fukushima H, Yoneda M, Anzai K, Aishima S, Nakajima A, Eguchi Y. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2020; 50:682-692. [PMID: 32090397 DOI: 10.1111/hepr.13495] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2020] [Revised: 02/14/2020] [Accepted: 02/18/2020] [Indexed: 02/08/2023]
Abstract
AIM The Enhanced Liver Fibrosis (ELF) test comprises a logarithmic algorithm combining three serum markers of hepatic extracellular matrix metabolism. We aimed to evaluate the performance of ELF for the diagnosis of liver fibrosis and to compare it with that of liver stiffness measurement (LSM) by FibroScan in non-alcoholic fatty liver disease. METHODS ELF cut-off values for the diagnosis of advanced fibrosis were obtained using receiver operating characteristic analysis in patients with biopsy-confirmed non-alcoholic fatty liver disease (training set; n = 200). Diagnostic performance was analyzed in the training set and in a validation set (n = 166), and compared with that of LSM in the FibroScan cohort (n = 224). RESULTS The area under receiver operating characteristic curve was 0.81 for the diagnosis of advanced fibrosis, and the ELF cut-off values were 9.34 with 90.4% sensitivity and 10.83 with 90.6% specificity in the training set, and 89.8% sensitivity and 85.5% specificity in the validation set. There was no significant difference in the area under the receiver operating characteristic curve between ELF and LSM (0.812 and 0.839). A combination of ELF (cut-off 10.83) and LSM (cut-off 11.45) increased the specificity to 97.9% and the positive predictive value, versus ELF alone. Sequential use of the Fibrosis-4 index (cut-off 2.67) and ELF (cut-off 9.34) increased the sensitivity to 95.9%. CONCLUSIONS ELF can identify advanced liver fibrosis in non-alcoholic fatty liver disease, and its diagnostic accuracy is comparable to that of FibroScan. According to the clinical setting, combinations or sequential procedures using other non-invasive tests complement the diagnostic performance of ELF for the identification of advanced fibrosis.
Collapse
Affiliation(s)
- Chika Inadomi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.,Liver Center, Saga University Hospital, Saga, Japan
| | - Hirokazu Takahashi
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.,Liver Center, Saga University Hospital, Saga, Japan
| | - Yuji Ogawa
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Satoshi Oeda
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.,Department of Clinical Laboratory Medicine, Saga University Hospital, Saga, Japan
| | - Kento Imajo
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yoshihito Kubotsu
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
| | - Kenichi Tanaka
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
| | - Takaomi Kessoku
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Michiaki Okada
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
| | | | - Takumi Akiyama
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
| | - Hideaki Fukushima
- Diagnostics Business Area, Siemens Healthcare Diagnostics K.K., Tokyo, Japan
| | - Masato Yoneda
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Keizo Anzai
- Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan
| | - Shinichi Aishima
- Department of Pathology & Microbiology, Faculty of Medicine, Saga University, Saga, Japan
| | - Atsushi Nakajima
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | |
Collapse
|
|
4
|
Takada M, Fukusaki M, Terao Y, Yamashita K, Inadomi C, Sumikawa K. Comparative efficacy of ropivacaine and bupivacaine for epidural block in outpatients with degenerative spinal disease and low back pain. ACTA ACUST UNITED AC 2013. [DOI: 10.1163/1568569054729481] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|